the helsinki heart study demonstrated a 34 % ( p less than 0.02 ) reduction in the incidence of cardiac end points ( myocardial infarction and cardiac death ) with the use of gemfibrozil compared with the use of a placebo in dyslipidemic middle-aged men .
C0018787
cardiac
C0027051
myocardial infarction